CSPC Pharmaceutical Group (HKEX: 1093) has confirmed receipt of a USD 1.2 billion upfront payment from AstraZeneca under the two firms' strategic collaboration and license agreement for long-acting peptide medicines signed in January this year. The upfront fee is one of the largest single upfront payouts ever recorded in a China-originated pharma out-licensing transaction. The deal grants AstraZeneca (NYSE: AZN) access to eight drug programs and two proprietary platforms developed by the Shijiazhuang-based pharmaceutical group.
Beyond the USD 1.2 billion upfront, the agreement carries up to USD 3.5 billion in development and regulatory milestones, up to USD 13.8 billion in sales-based milestones, and tiered royalties described as reaching up to double-digit percentages on annual net sales — bringing the theoretical total deal value to USD 18.5 billion across all eight programs.
Deal context
The eight programs span two categories: four existing assets, including the lead candidate SYH2082, a long-acting dual GLP-1 receptor and GIP receptor agonist described by CSPC as clinical-ready and advancing into Phase I, alongside three preclinical programs with undisclosed targets in obesity and type 2 diabetes. Four additional programs will be jointly originated under the collaboration framework using CSPC's platforms, with CSPC responsible for advancing them through Phase I before AstraZeneca assumes global development leadership outside Greater China.
The technology at the center of the arrangement is CSPC's proprietary LiquidGel sustained-release delivery platform, an injectable depot system designed to achieve once-monthly dosing for peptide drugs. Based on its described characteristics — injectable as a liquid, forming a semi-solid depot at the injection site, with no reconstitution required — LiquidGel is consistent with the established class of in situ-forming injectable depot systems, in which a phase transition triggered by body temperature or solvent exchange creates a sustained-release matrix. CSPC has not publicly disclosed the precise chemistry underlying the platform.
The practical significance of once-monthly dosing is material in the GLP-1 landscape, where the current standard of care — semaglutide and tirzepatide — requires weekly injections. A shift to monthly administration, if validated clinically, would represent a meaningful differentiation in patient convenience and adherence. AstraZeneca secured not only rights to the eight named programs but also the right to deploy LiquidGel across its own internal development pipeline, a provision that signals the platform is being licensed as a standalone enabling technology.